R1 RCM (NASDAQ:RCM) Releases FY 2021 Earnings Guidance


Share on StockTwits

R1 RCM (NASDAQ:RCM) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $1.41 billion-$1.46 billion, compared to the consensus revenue estimate of $1.45 billion.

Shares of NASDAQ RCM traded down $3.32 during trading hours on Tuesday, reaching $23.85. The stock had a trading volume of 6,064,182 shares, compared to its average volume of 1,031,847. The business’s fifty day moving average is $25.58 and its two-hundred day moving average is $23.98. The company has a debt-to-equity ratio of 8.74, a current ratio of 1.59 and a quick ratio of 1.59. The company has a market cap of $6.23 billion, a price-to-earnings ratio of 259.14, a PEG ratio of 4.00 and a beta of 0.91. R1 RCM has a twelve month low of $8.34 and a twelve month high of $31.28.

R1 RCM (NASDAQ:RCM) last announced its quarterly earnings results on Thursday, February 18th. The healthcare provider reported $0.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.06. R1 RCM had a return on equity of 117.07% and a net margin of 3.69%. The firm had revenue of $328.40 million for the quarter, compared to analysts’ expectations of $316.65 million. Sell-side analysts forecast that R1 RCM will post 0.25 earnings per share for the current fiscal year.

Several analysts have recently commented on RCM shares. Cowen increased their target price on R1 RCM from $22.00 to $33.00 and gave the stock an outperform rating in a report on Tuesday, February 9th. Zacks Investment Research upgraded R1 RCM from a sell rating to a hold rating in a report on Thursday, April 22nd. Finally, KeyCorp increased their target price on R1 RCM from $27.00 to $35.00 in a report on Tuesday, February 16th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. R1 RCM currently has a consensus rating of Buy and a consensus target price of $28.60.

In other news, COO John M. Sparby sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, February 24th. The stock was sold at an average price of $28.66, for a total transaction of $859,800.00. Following the sale, the chief operating officer now owns 310,854 shares of the company’s stock, valued at $8,909,075.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO John M. Sparby sold 17,450 shares of the firm’s stock in a transaction dated Friday, February 26th. The stock was sold at an average price of $28.01, for a total value of $488,774.50. Following the sale, the chief operating officer now directly owns 202,843 shares in the company, valued at approximately $5,681,632.43. The disclosure for this sale can be found here. Insiders sold 149,761 shares of company stock worth $4,056,071 in the last three months. Insiders own 59.40% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

Read More: Trade War

Earnings History and Estimates for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.